SCHEMBL6350588

SCHEMBL6350588

c1ccc2nc(N3CCCNCC3)cnc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.62
▸ CHRNA4 P43681 2/20 0.62
▸ NPC1 O15118 6/20 0.59
▸ RAB9A P51151 6/20 0.59
▸ MAPT P10636 5/20 0.59
▸ ALDH1A1 P00352 4/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ HTR3A P46098 2/20 0.59
▸ HTT P42858 2/20 0.59
▸ NFKB1 P19838 2/20 0.59
▸ NFKB2 Q00653 2/20 0.59
▸ RELA Q04206 2/20 0.59
▸ HRH4 Q9H3N8 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ KDM4E B2RXH2 3/20 0.56
▸ ADRB1 P08588 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ HTR3E A5X5Y0 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2114532 0.94 NPC1 (0.66) CHRNB2CHRNA4NPC1RAB9AMAPT
Hydrochloric Acid SCHEMBL4056910 0.92 NPC1 (0.64) CHRNB2CHRNA4NPC1RAB9AMAPT
SCHEMBL17043892 0.92 NPC1 (0.64) CHRNB2CHRNA4NPC1RAB9AMAPT
SCHEMBL31184151 0.85 NPC1 (0.72) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL29832295 0.85 NPC1 (0.72) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL31753893 0.84 NPC1 (0.58) CHRNB2CHRNA4NPC1RAB9AMAPT
SCHEMBL3552442 0.84 NPC1 (0.70) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL31326693 0.84 ALDH1A1 (0.55) CHRNB2CHRNA4NPC1RAB9AMAPT
SCHEMBL3227424 0.80 KDM4E (0.88) CHRNB2CHRNA4NPC1RAB9AALDH1A1
SCHEMBL1713999 0.77 NPC1 (0.70) NPC1RAB9AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 — — US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 — — US disclosed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 — — EP disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 — — US disclosed
EP-1027336-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2000-08-16 — — EP disclosed
WO-1999021834-A1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 1999-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 CHRNB2 700/4885CHRNA4 1019/4885NPC1 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback